PsAID12 provisionally endorsed at OMERACT 2018 as core outcome measure to assess psoriatic arthritis-specific health-related quality of life in clinical trials

<p><strong>Objective</strong> The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and Outcome Measures in Rheumatology (OMERACT) psoriatic arthritis (PsA) working group is developing a Core Outcome Measurement Set for PsA clinical trials [randomized...

Full description

Bibliographic Details
Main Authors:	Orbai, A, Holland, R, Leung, Y, Tillett, W, Goel, N, Christensen, R, McHugh, N, Gossec, L, De Wit, M, Højgaard, P, Coates, L, Mease, P, Lindsay, C, Birt, J, Fallon, L, FitzGerald, O, Ogdie, A, Shea, B, Strand, V, Veale, D, Callis-Duffin, K, Tugwell, P, Beaton, D, Gladman, D
Format:	Journal article
Published:	Journal of Rheumatology Publishing Co. Ltd 2018

PsAID12 provisionally endorsed at OMERACT 2018 as core outcome measure to assess psoriatic arthritis-specific health-related quality of life in clinical trials

Similar Items